Proyecto
 (2007)

BLISS 52, A phase III study, multi-center randomized, double blind, placebo controlled, of 52-week duration, to evaluate the efficacy and safety of Belimumab (HGS1006, LymphoStat-BTM), anti BLyS human monoclonal antibody, in the treatment of patients with active SLE.

Massardo, Loreto